Article Sidebar
Published:
Aug 25, 2022Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Dolutegravir drug-drug interactions
Abstract
Dolutegravir is neither an inducer nor an inhibitor of metabolising enzymes, and it therefore has a low propensity to act as a perpetrator of drug-drug interactions. Clinically significant decreases in dolutegravir exposure occur when it is co-administered with strong inducers (e.g. rifampicin, efavirenz) of drug metabolising enzymes and drug efflux transporters for which dolutegravir is a substrate – this can be overcome by increasing the dose of dolutegravir from 50 mg once daily to 50 mg twice daily. Dolutegravir significantly increases metformin plasma exposure: one must not exceed metformin 500 mg twice daily with concomitant dolutegravir. Divalent or trivalent cations chelate dolutegravir. Therefore, concomitant administration of dolutegravir with aluminium- and calcium-containing antacids should be avoided. Dolutegravir can be administered with calcium and iron supplements, provided these are taken together with food.
